Glaukos outlines $680M-$700M 2026 net sales as iDose TR seen at $275M-$280M (NYSE:GKOS)
· seekingalpha.com
Glaukos (GKOS) Q2 2026 earnings call: record sales, raised 2026 guidance, iDose TR/Epioxa growth, margin outlook & risks.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...